What are the dominant cytokines in early rheumatoid arthritis?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose of review: Rheumatoid arthritis is a systemic disease of evolving immune dysregulation that culminates in joint destruction and disability. The principle by which pro-inflammatory cytokines may be therapeutically targeted to abrogate disease is well established, but has yet to translate into reliable cures for patients. Emerging insights into cytokine-mediated pathobiology during rheumatoid arthritis development are reviewed, and their implications for future treatment strategies considered. Recent findings: Accumulating data highlight cytokine perturbations before the clinical onset of rheumatoid arthritis. Some of these have now been linked to the arthritogenic activation of autoantibodies and associated pain and bone destruction in affected joints. These observations suggest cytokines may trigger the transition from systemic immunity to arthritis. Cytokine exposure could furthermore ‘prime’ synovial stromal cells to perpetuate a dominant pro-inflammatory environment. By facilitating cross-talk between infiltrating immune cells and even sustaining ectopic lymphoid structure development in some cases, cytokine interplay ultimately underpins the failure of arthritis to resolve. Summary: Successful therapeutic stratification will depend upon an increasingly sophisticated appreciation of how dominant players amongst cytokine networks vary across time and anatomical space during incipient rheumatoid arthritis. The prize of sustained remission for all patients justifies the considerable effort required to achieve this understanding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunopathogenesis of Rheumatoid Arthritis
Firestein, G. S., & McInnes, I. B. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.006 · Cited by 1,301
Blanco, F. J., Möricke, R., Dokoupilova, E., Codding, C., Neal, J., Andersson, M., Rohrer, S., & Richards, H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40070 · Cited by 185
Cited by
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
Ridgley, L. A., Anderson, A. E., Maney, N. J., Naamane, N., Skelton, A. J., Lawson, C. A., Emery, P., Isaacs, J. D., Carmody, R. J., & Pratt, A. G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01535 · Cited by 27
“An increasingly sophisticated appreciation of its complex biology (7), together with growing evidence for its uniquely important role in early disease (1, 33) now warrants a reappraisal of therapeutic strategy.”
BackgroundSelf-citation
Metadata
- Authors
- Ridgley, L. A., Anderson, A. E., & Pratt, A. G.
- Venue
- Current Opinion in Rheumatology
- Published
- 2018-03
- Volume
- 30
- Issue
- 2
- Pages
- 207-214
- ISSN
- 1040-8711 (ISSN-L)
- 1531-6963
- OpenAlex
- W2772227551
- Cited by
- 165
- References
- 2
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What are the dominant cytokines in early rheumatoid arthritis? https://app.cochat.ai/papers/10.1097/bor.0000000000000470
- The paper
- Ridgley, L. A., Anderson, A. E., & Pratt, A. G. (2018). What are the dominant cytokines in early rheumatoid arthritis? Current Opinion in Rheumatology. https://doi.org/10.1097/bor.0000000000000470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.